

## DRUG QUANTITY MANAGEMENT POLICY – PER RX

**POLICY:** Oncology – Doptelet Drug Quantity Management Policy – Per Rx

- Doptelet® (avatrombopag tablets – AkaRx)

**REVIEW DATE:** 06/15/2022

---

### OVERVIEW

Doptelet, a thrombopoietin receptor agonist, is indicated for the following uses:<sup>1</sup>

- **Immune thrombocytopenia**, chronic for treatment in adults who have had an insufficient response to a previous treatment.
- **Chronic liver disease**, adults with **thrombocytopenia** as a treatment for who are scheduled to undergo a procedure.

### Dosing

#### Chronic Liver Disease

Doptelet therapy should be initiated 10 to 13 days prior to the patient’s scheduled procedure and administered orally once daily (QD) for 5 consecutive days with food.<sup>1</sup> The procedure should then take place 5 to 8 days after the final dose of Doptelet. The recommended dose of Doptelet is dependent on the patient’s platelet count:

- Platelet count < 40 x 10<sup>9</sup>/L: 60 mg (3 tablets) QD x 5 days.
- Platelet count 40 to < 50 x 10<sup>9</sup>/L: 40 mg (2 tablets) QD x 5 days.

#### Chronic Immune Thrombocytopenia

The recommended dose of Doptelet is the lowest dose needed to achieve and maintain a platelet count  $\geq 50$  x 10<sup>9</sup>/L as needed to reduce the patient’s risk for bleeding. Initiate Doptelet therapy at a dose of 20 mg (1 tablet) QD administered with food. After initial therapy, assess platelet counts weekly until a stable count  $\geq 50$  x 10<sup>9</sup>/L is achieved. Then, obtain platelet counts monthly thereafter. Dose adjustments should be made based on the patient’s platelet count response (Table 1). Do not exceed a dose of 40 mg (2 tablets) QD. Doptelet should not be used to normalize platelet counts.

**Table 1. Chronic Immune Thrombocytopenia Doptelet Dose Adjustments.<sup>1</sup>**

Platelet Count (x 10 <sup>9</sup> /L)	Dose Adjustment or Action
< 50 x 10 <sup>9</sup> /L after at least 2 weeks of Doptelet	Increase One Dose Level per Table 2. Wait 2 weeks to assess the effects of this regimen and any subsequent dose adjustments.
Between 200 and 400 x 10 <sup>9</sup> /L	Decrease One Dose Level per Table 2. Wait 2 weeks to assess the effects of this regime and any subsequent dose adjustments.
> 400 x 10 <sup>9</sup> /L	Stop Doptelet. Increase platelet monitoring to twice weekly. When platelet count is < 150 x 10 <sup>9</sup> /L, decrease One Dose Level per Table 2 and reinstate therapy.
< 50 x 10 <sup>9</sup> /L after 4 weeks of Doptelet 40 mg QD	Discontinue Doptelet.
> 400 x 10 <sup>9</sup> /L after 2 weeks of Doptelet 20 mg weekly	Discontinue Doptelet.

QD – Once daily.

06/15/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

**Table 2. Doptelet Dose Levels for Titration in Patients with Chronic Immune Thrombocytopenia.<sup>1</sup>**

Dose	Dose Level
40 mg QD	6
40 mg three times per week AND 20 mg four times per week (remaining days)	5
20 mg QD	4
20 mg three time per week	3
20 mg two time per week OR 40 mg once weekly	2
20 mg once weekly	1

QD – Once daily.

The recommended starting dose for a patient taking Doptelet with a moderate or strong dual inhibitor of cytochrome P450 (CYP)2C9 and CYP3A4 is 20 mg (1 tablet) three times per week.<sup>1</sup> If the patient is taking Doptelet with a moderate or strong dual inducer of CYP2C9 and CYP3A4, the initial recommended dose is 40 mg (2 tablets) QD.

### Availability

Doptelet is available as 20 mg tablets supplied in the following:<sup>1</sup>

- Carton of one blister card with 10 tablets
- Carton of one blister card with 15 tablets
- Carton of two blister cards, each with 15 tablets (30 tablets total)

### POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Doptelet. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

**Automation:** None.

### Drug Quantity Limits

Product	Strength and Form	Maximum Quantity per Rx
Doptelet® (avatrombopag tablets)	20 mg tablets	15 tablets*

\* This is a quantity sufficient for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.

### CRITERIA

1. If the patient requires treatment for chronic immune thrombocytopenia, approve the requested quantity, not to exceed 60 tablets per dispensing.

### REFERENCES

1. Doptelet® tablets [prescribing information]. Durham, NC: AkaRx; June 2021.

